CARMEL, Ind., Nov. 14, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023.
Q3 2023 Financial Highlights
Recent Operational Highlights
Management Commentary
Dr. Deepika Vuppalanchi, CEO of Syra Health, said, "Our current and future pipeline of contracts is expanding, and we expect to announce contract wins as they are solidified. I look forward to building upon our recent successes to fulfill our promise of improving healthcare while driving value for our shareholders."
Sandeep Allam, Executive Chairman and President of Syra Health, said, "We completed our successful initial public offering in October 2023. During the third quarter, we also saw our first revenues from our Digital Health business unit and expect revenue growth to continue as several products are launched. We also saw growth in our Population Health and Health Education Business Units. We are pleased with our third quarter performance and all that we have accomplished. We look forward to our continued growth and innovation next quarter and beyond."
Q3 2023 Financial Results
Revenue for the quarter ended September 30, 2023, was $1.58 million, compared to the $1.51 million reported in the third quarter of 2022. Strong growth in the Digital Health, Population Health, and Health Education business units was offset by our Healthcare Workforce.
Gross profit for the quarter ended September 30, 2023, was $554,541, reflecting a gross profit margin of 35.1%, compared to $413,809 million, or a gross profit margin of 27.3%, in the third quarter of 2022. The increase in gross margins was due to a slight shift from healthcare staffing services to medical communication and digital health services that carry better margins.
Total operating expenses for the third quarter of 2023 increased 18% to $897,557, compared to $760,600 in the third quarter of 2022. Salaries and benefits expenses increased 31%, compared to the third quarter of 2022 due to increased operations and added office personnel to support the Company's IPO process. Professional fees declined 62%, compared to the third quarter of 2022 due to decreased reliance on outsourced professional fees in connection with the prior period audit in preparation for the Company's IPO. Selling, general and administrative expenses increased 56%, compared to the third quarter of 2022 due to increased operations. Depreciation expense was $14,180 in the third quarter of 2023, compared to $3,880 for the same period last year, reflecting expanded office space.
Net Loss for the quarter ended September 30, 2023, was $(354,376), compared to $(354,535) in the third quarter of 2022.
Adjusted EBITDA (see Table A) for the quarter ended September 30, 2023, was $(329,580), compared to $(341,760) in the third quarter of 2022.
Cash on hand September 30, 2023, was $18,010. Upon the closing of its IPO on October 3, 2023, the Company collected net proceeds of $4.7M.
Conference Call
Management will hold a conference call to discuss the quarter's financial results at 9:00am ET on November 14, 2023.
Interested parties can listen via a live webcast, from the link available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations or via https://app.webinar.net/QnrqX7vAKVL.
A replay will be available after the call, in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations .
Non-GAAP Financial Measures
In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use these non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity, and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. We define Adjusted EBITDA as net earnings (loss) before (i) interest income, (ii) interest expense, (iii) change in allowance for doubtful accounts, (iv) depreciation, and (v) non-cash expenses relating to share-based payments recognized under ASC Topic 718. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see Table A accompanying this release.
SYRA HEALTH CORP. | |||||||
RECONCILIATION OF ADJUSTED EBITDA TO NET LOSS | |||||||
(Unaudited) | |||||||
For the Three Months Ended | For the Nine Months Ended | ||||||
September 30, | September 30, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Net loss | $ (354,376) | $ (354,535) | $(1,943,068) | $(1,505,533) | |||
Add back: | |||||||
Interest income | (2,820) | (35) | (2,826) | (54) | |||
Interest expense | 14,180 | 7,779 | 44,449 | 16,641 | |||
Change in allowance for doubtful accounts | - | - | 986 | - | |||
Depreciation | 12,357 | 3,880 | 36,413 | 4,791 | |||
Stock based compensation | 1,079 | 1,151 | 3,669 | 511,151 | |||
Adjusted EBITDA | $ (329,580) | $ (341,760) | $(1,860,377) | $ (973,004) | |||
ABOUT SYRA HEALTH
Syra Health is a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health's solutions are centered on prevention, improved access, and affordable care. For more information, please visit www.syrahealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Investors should read the risk factors set forth in our Form 10-Q for the quarter ended September 30, 2023, and in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syra Health specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Media:
Syra Health
Communications & Marketing Director
Christine Drury
317-385-9227
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
SYRA HEALTH CORP. CONDENSED BALANCE SHEETS | ||||||||
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
ASSETS | (Unaudited) | |||||||
Current assets: | ||||||||
Cash | $ | 18,010 | $ | 3,344 | ||||
Accounts receivable, net | 1,054,851 | 1,201,097 | ||||||
Other current assets | 163,323 | 222,302 | ||||||
Total current assets | 1,236,184 | 1,426,743 | ||||||
Deferred offering costs | 1,185,177 | 596,118 | ||||||
Property and equipment, net | 91,331 | 112,493 | ||||||
Right-of-use asset | 94,126 | 184,288 | ||||||
Total assets | $ | 2,606,818 | $ | 2,319,642 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 932,779 | $ | 432,388 | ||||
Accounts payable, related parties | 21,421 | 3,200 | ||||||
Accrued expenses | 274,596 | 239,117 | ||||||
Deferred revenue | 141,644 | - | ||||||
Current portion of operating lease liability, related party | 94,126 | 121,089 | ||||||
Revolving line of credit | 300,154 | 750,551 | ||||||
Advances from related party | 616,399 | - | ||||||
Total current liabilities | 2,381,119 | 1,546,345 | ||||||
Operating lease liability, related party | - | 63,199 | ||||||
Convertible notes payable | 1,455,000 | - | ||||||
Total liabilities | 3,836,119 | 1,609,544 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity (deficit): | ||||||||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, | - | - | ||||||
Class A common stock, $0.001 par value, 100,000,000 shares | ||||||||
shares issued and outstanding at September 30, 2023 and | 3,527 | 3,569 | ||||||
Convertible class B common stock, $0.001 par value, 5,000,000 | 833 | 833 | ||||||
Additional paid-in capital | 2,836,019 | 2,832,308 | ||||||
Accumulated deficit | (4,069,680) | (2,126,612) | ||||||
Total stockholders' equity (deficit) | (1,229,301) | 710,098 | ||||||
Total liabilities and stockholders' equity (deficit) | $ | 2,606,818 | $ | 2,319,642 | ||||
SYRA HEALTH CORP. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net revenues: | ||||||||||||||||
Healthcare staffing services | $ | 1,121,238 | $ | 1,447,979 | $ | 3,103,940 | $ | 3,366,667 | ||||||||
Medical communication services | 328,750 | 66,000 | 513,647 | 285,311 | ||||||||||||
Digital health services | 131,356 | - | 131,356 | - | ||||||||||||
Net revenues | 1,581,344 | 1,513,979 | 3,748,943 | 3,651,978 | ||||||||||||
Cost of services | 1,026,803 | 1,100,170 | 2,919,087 | 2,881,142 | ||||||||||||
Gross profit | 554,541 | 413,809 | 829,856 | 770,836 | ||||||||||||
Operating expenses: | ||||||||||||||||
Salaries and benefits | 592,241 | 451,771 | 1,612,605 | 1,021,627 | ||||||||||||
Professional services | 58,875 | 154,457 | 424,379 | 863,297 | ||||||||||||
Selling, general and | 234,084 | 150,492 | 657,904 | 370,067 | ||||||||||||
Depreciation | 12,357 | 3,880 | 36,413 | 4,791 | ||||||||||||
Total operating expenses | 897,557 | 760,600 | 2,731,301 | 2,259,782 | ||||||||||||
Operating loss | (343,016) | (346,791) | (1,901,445) | (1,488,946) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest income | 2,820 | 35 | 2,826 | 54 | ||||||||||||
Interest expense | (14,180) | (7,779) | (44,449) | (16,641) | ||||||||||||
Total other income (expense) | (11,360) | (7,744) | (41,623) | (16,587) | ||||||||||||
Net loss | $ | (354,376) | $ | (354,535) | $ | (1,943,068) | $ | (1,505,533) | ||||||||
Weighted average common shares | 4,360,426 | 4,107,164 | 4,380,267 | 2,337,915 | ||||||||||||
Net loss per common share - basic | $ | (0.08) | $ | (0.09) | $ | (0.44) | $ | (0.64) | ||||||||
| Last Trade: | US$0.40 |
| Daily Change: | 0.02 5.99 |
| Daily Volume: | 55,080 |
| Market Cap: | US$3.590M |
September 13, 2024 August 08, 2024 July 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
